Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Samsung Bioepis Co. Ltd.

Division of Samsung Electronics Co. Ltd.
www.samsungbioepis.com

Latest From Samsung Bioepis Co. Ltd.

US Insurer United Rewards Amgen’s Early Entry With Bevacizumab And Trastuzumab

Amgen’s Mvasi and Kanjinti alternatives to Roche’s Avastin bevacizumab and Herceptin trastuzumab brands will from 1 October be preferred by plans administered by the largest US health insurer, UnitedHealthcare.

Biosimilars United States

Advances On the Biosimilar Litigation Battlefield

A look at the evolution of litigation, from Amgen's 'bold' at-risk launch of Herceptin and Avastin biosimilars to the jump in settlements, new battles over manufacturing information and an expected petition to the Supreme Court.

Biosimilars Intellectual Property

Amgen Could Block Enbrel Biosimilars For Another Decade As Court Rules Stealth Patents Valid

Court rejects Sandoz's arguments that patents covering Enbrel's active ingredient and method of manufacture are invalid; decision comes three years after FDA approved Sandoz's biosimilar.

Biosimilars Intellectual Property

Amgen’s Future Looks Brighter After Ruling Lifts Threat Of Enbrel Copycat

Markets are re-assessing Amgen’s long-term value after a US judge upheld two patents relating to Amgen's blockbuster rheumatoid arthritis drug Enbrel, denying a challenge by Novartis and allowing investors to focus now on the pharma’s promising pipeline.

Commercial Companies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • Samsung Electronics Co. Ltd.
  • Senior Management
  • Christopher Hansung Ko, PhD, CEO
  • Contact Info
  • Samsung Bioepis Co. Ltd.
    Phone: 32 455 3114
    107, Cheomdan-daero
    Yeonsu-Gu
    Incheon, 406-840
    South Korea
Advertisement
Advertisement
UsernamePublicRestriction

Register